Tagrisso 80 Mg

Tagrisso 80 mg

Description: Tagrisso 80 mg is an oral medication used for the treatment of non-small cell lung cancer (NSCLC) with specific genetic mutations. It contains Osimertinib, a targeted therapy designed to treat advanced or metastatic NSCLC that is positive for epidermal growth factor receptor (EGFR) mutations, particularly those resistant to other EGFR inhibitors.

Salt Composition:

• Osimertinib (80 mg): A selective EGFR tyrosine kinase inhibitor (TKI) that targets specific mutations to slow down or stop the growth of cancer cells.

Key Features:

• Targeted Therapy: Specifically designed to target EGFR mutations associated with NSCLC.
• Oral Administration: Taken as a daily oral tablet, providing a convenient option for long-term management.
• Resistance Management: Effective in treating cancers resistant to first and second-generation EGFR inhibitors.

Benefits:

• Effective Against Specific Mutations: Provides targeted treatment for NSCLC with EGFR mutations, including T790M mutation.
• Improves Outcomes: Can enhance progression-free survival and overall response rates in advanced NSCLC.
• Convenient Dosing: Oral formulation allows for ease of use and patient adherence.

American Brand Names:

• Tagrisso

Indian Brand Names:

• Tagrisso 80 mg
• Osimertinib Tablets (Various local brands)

Related Keywords: Tagrisso 80 mg, Osimertinib, EGFR TKI, non-small cell lung cancer treatment, targeted cancer therapy, advanced NSCLC, oral cancer medication, Tagrisso brands, cancer mutation treatment.